{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:43:48Z","timestamp":1787672628914,"version":"build-2736575974"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470566"],"award-info":[{"award-number":["81470566"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670765"],"award-info":[{"award-number":["81670765"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070841"],"award-info":[{"award-number":["82070841"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.addr.2021.01.004","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T21:53:04Z","timestamp":1610056384000},"page":"234-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Nanomedicine for the treatment of diabetes-associated cardiovascular diseases and fibrosis"],"prefix":"10.1016","volume":"172","author":[{"given":"Xiao-Min","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Mei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.01.004_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2337\/dbi17-0013","article-title":"Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication","volume":"67","author":"Hu","year":"2018","journal-title":"Diabetes."},{"key":"10.1016\/j.addr.2021.01.004_bb0010","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Factors","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.01.004_bb0015","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation."},{"key":"10.1016\/j.addr.2021.01.004_bb0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.addr.2021.01.004_bb0025","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s10753-019-00989-0","article-title":"Correction to: Plumbagin Prevents IL-1beta-Induced Inflammatory Response in Human Osteoarthritis Chondrocytes and Prevents the Progression of Osteoarthritis in Mice","volume":"42","author":"Zheng","year":"2019","journal-title":"Inflammation."},{"key":"10.1016\/j.addr.2021.01.004_bb0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nri3800","article-title":"Role of innate and adaptive immune mechanisms in cardiac injury and repair","volume":"15","author":"Epelman","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.004_bb0035","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.004_bb0040","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.addr.2021.01.004_bb0045","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819834869","article-title":"Diabetic cardiomyopathy: prevalence, determinants and potential treatments","volume":"10","author":"Gulsin","year":"2019","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2021.01.004_bb0050","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1161\/CIRCULATIONAHA.111.022327","article-title":"Myocardial structure, function, and scar in patients with type 1 diabetes mellitus","volume":"124","author":"Turkbey","year":"2011","journal-title":"Circulation."},{"key":"10.1016\/j.addr.2021.01.004_bb0055","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/00015385.2017.1410350","article-title":"Fragmented QRS complexes are associated with left ventricular dysfunction in patients with type-2 diabetes mellitus: a two-dimensional speckle tracking echocardiography study","volume":"73","author":"Bayramoglu","year":"2018","journal-title":"Acta Cardiol."},{"key":"10.1016\/j.addr.2021.01.004_bb0060","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.120.011000","article-title":"Examining the Relationship and Prognostic Implication of Diabetic Status and Extracellular Matrix Expansion by Cardiac Magnetic Resonance","volume":"13","author":"Khan","year":"2020","journal-title":"Circ. Cardiovasc. Imaging."},{"key":"10.1016\/j.addr.2021.01.004_bb0065","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.carpath.2014.03.004","article-title":"Investigating inherent functional differences between human cardiac fibroblasts cultured from nondiabetic and Type 2 diabetic donors","volume":"23","author":"Sedgwick","year":"2014","journal-title":"Cardiovasc Pathol."},{"key":"10.1016\/j.addr.2021.01.004_bb0070","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00125-012-2495-3","article-title":"Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db\/db mouse model of type 2 diabetes","volume":"55","author":"Huynh","year":"2012","journal-title":"Diabetologia."},{"key":"10.1016\/j.addr.2021.01.004_bb0075","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.lfs.2013.01.003","article-title":"Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts","volume":"92","author":"Fowlkes","year":"2013","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2021.01.004_bb0080","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1210\/en.2013-1096","article-title":"Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats","volume":"154","author":"Aroor","year":"2013","journal-title":"Endocrinology."},{"key":"10.1016\/j.addr.2021.01.004_bb0085","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.diabet.2018.07.003","article-title":"Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways","volume":"45","author":"Joubert","year":"2019","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.addr.2021.01.004_bb0090","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.bbalip.2016.02.016","article-title":"Lipid metabolism and signaling in cardiac lipotoxicity","volume":"1861","author":"D'Souza","year":"2016","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.addr.2021.01.004_bb0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00125-017-4390-4","article-title":"Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease","volume":"61","author":"Jia","year":"2018","journal-title":"Diabetologia."},{"key":"10.1016\/j.addr.2021.01.004_bb0100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res."},{"key":"10.1016\/j.addr.2021.01.004_bb0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrendo.2015.216","article-title":"Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy","volume":"12","author":"Jia","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.addr.2021.01.004_bb0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.addr.2021.01.004_bb0115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.yjmcc.2013.11.015","article-title":"Fibroblasts in myocardial infarction: a role in inflammation and repair","volume":"70","author":"Shinde","year":"2014","journal-title":"J Mol Cell Cardiol."},{"key":"10.1016\/j.addr.2021.01.004_bb0120","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.nefro.2016.06.011","article-title":"Cystatin-C and TGF-beta levels in patients with diabetic nephropathy","volume":"36","author":"Takir","year":"2016","journal-title":"Nefrologia."},{"key":"10.1016\/j.addr.2021.01.004_bb0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1523-1755.2004.00393.x","article-title":"Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad\/TGF-beta signaling","volume":"65","author":"Fukasawa","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.01.004_bb0130","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/jcp.26959","article-title":"Circular RNA circRNA_15698 aggravates the extracellular matrix of diabetic nephropathy mesangial cells via miR-185\/TGF-beta1","volume":"234","author":"Hu","year":"2019","journal-title":"J Cell Physiol."},{"key":"10.1016\/j.addr.2021.01.004_bb0135","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3390\/nu10070882","article-title":"Chrysin Inhibits Advanced Glycation End Products-Induced Kidney Fibrosis in Renal Mesangial Cells and Diabetic Kidneys","volume":"10","author":"Lee","year":"2018","journal-title":"Nutrients."},{"key":"10.1016\/j.addr.2021.01.004_bb0140","doi-asserted-by":"crossref","first-page":"47257","DOI":"10.1074\/jbc.M208573200","article-title":"Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for activation of p38alpha and p38delta MAPK isoforms by TGF-beta 1 in murine mesangial cells","volume":"277","author":"Wang","year":"2002","journal-title":"J Biol Chem."},{"key":"10.1016\/j.addr.2021.01.004_bb0145","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.yexcr.2013.03.030","article-title":"SDF-1alpha reduces fibronectin expression in rat mesangial cells induced by TGF-beta1 and high glucose through PI3K\/Akt pathway","volume":"319","author":"Zhang","year":"2013","journal-title":"Exp Cell Res."},{"key":"10.1016\/j.addr.2021.01.004_bb0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.14715\/cmb\/2018.64.5.22","article-title":"TGFbeta1-mediated PI3K\/Akt and p38 MAP kinase dependent alternative splicing of fibronectin extra domain A in human podocyte culture","volume":"64","author":"Madne","year":"2018","journal-title":"Cell. Mol. Biol. (Noisy-le-grand)."},{"key":"10.1016\/j.addr.2021.01.004_bb0155","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/aps.2017.184","article-title":"SND p102 promotes extracellular matrix accumulation and cell proliferation in rat glomerular mesangial cells via the AT1R\/ERK\/Smad3 pathway","volume":"39","author":"Xu","year":"2018","journal-title":"Acta Pharmacol Sin."},{"key":"10.1016\/j.addr.2021.01.004_bb0160","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2353\/ajpath.2009.090096","article-title":"Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice","volume":"175","author":"Li","year":"2009","journal-title":"Am J Pathol."},{"key":"10.1016\/j.addr.2021.01.004_bb0165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.phymed.2017.10.008","article-title":"Poricoic acid ZA, a novel RAS inhibitor, attenuates tubulo-interstitial fibrosis and podocyte injury by inhibiting TGF-beta\/Smad signaling pathway","volume":"36","author":"Wang","year":"2017","journal-title":"Phytomedicine."},{"key":"10.1016\/j.addr.2021.01.004_bb0170","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1681\/ASN.2012101041","article-title":"Kindlin-2 mediates activation of TGF-beta\/Smad signaling and renal fibrosis","volume":"24","author":"Wei","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.addr.2021.01.004_bb0175","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/nrm2297","article-title":"TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility","volume":"8","author":"Schmierer","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2021.01.004_bb0180","doi-asserted-by":"crossref","first-page":"4025496","DOI":"10.1155\/2019\/4025496","article-title":"Upregulation of Transient Receptor Potential Canonical Type 3 Channel via AT1R\/TGF-beta1\/Smad2\/3 Induces Atrial Fibrosis in Aging and Spontaneously Hypertensive Rats","volume":"2019","author":"He","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.addr.2021.01.004_bb0185","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1161\/HYPERTENSIONAHA.116.08215","article-title":"A Novel Mechanism of Action for Angiotensin-(1-7) via the Angiotensin Type 1 Receptor","volume":"68","author":"Nicklin","year":"2016","journal-title":"Hypertension."},{"key":"10.1016\/j.addr.2021.01.004_bb0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11010-018-3331-y","article-title":"Intracrine action of angiotensin II in mesangial cells: subcellular distribution of angiotensin II receptor subtypes AT1 and AT2","volume":"448","author":"da Silva Novaes","year":"2018","journal-title":"Mol Cell Biochem."},{"key":"10.1016\/j.addr.2021.01.004_bb0195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00109-015-1343-6","article-title":"Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy","volume":"94","author":"Ding","year":"2016","journal-title":"J. Mol. Med. (Berl.)."},{"key":"10.1016\/j.addr.2021.01.004_bb0200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbrc.2015.11.092","article-title":"Silencing of angiotensin II type-1 receptor inhibits high glucose-induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells via inactivation of mTOR\/p70S6K signaling pathway","volume":"469","author":"Gong","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2021.01.004_bb0205","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1172\/JCI11951","article-title":"Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)","volume":"108","author":"Oldfield","year":"2001","journal-title":"J Clin Invest."},{"key":"10.1016\/j.addr.2021.01.004_bb0210","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic Mechanisms of Diabetic Heart Disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ Res."},{"key":"10.1016\/j.addr.2021.01.004_bb0215","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/s41598-017-16255-y","article-title":"Pyridoxamine improves survival and limits cardiac dysfunction after MI","volume":"7","author":"Deluyker","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.004_bb0220","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fphys.2012.00292","article-title":"Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling","volume":"3","author":"Kranstuber","year":"2012","journal-title":"Front. Physiol."},{"key":"10.1016\/j.addr.2021.01.004_bb0225","doi-asserted-by":"crossref","first-page":"16084","DOI":"10.1038\/s41598-018-33886-x","article-title":"Cardiac troponins may be irreversibly modified by glycation: novel potential mechanisms of cardiac performance modulation","volume":"8","author":"Janssens","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.004_bb0230","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijcard.2014.01.011","article-title":"Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy","volume":"172","author":"Wang","year":"2014","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.addr.2021.01.004_bb0235","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/j.ajkd.2004.08.039","article-title":"Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy","volume":"45","author":"Sakai","year":"2005","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.addr.2021.01.004_bb0240","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00011-013-0675-3","article-title":"Inflammatory factor-specific sumoylation regulates NF-kappaB signalling in glomerular cells from diabetic rats","volume":"63","author":"Chen","year":"2014","journal-title":"Inflamm Res."},{"key":"10.1016\/j.addr.2021.01.004_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104771","article-title":"NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model","volume":"9","author":"Luo","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.addr.2021.01.004_bb0250","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1042\/BCJ20160556","article-title":"NOD1 activation in cardiac fibroblasts induces myocardial fibrosis in a murine model of type 2 diabetes","volume":"474","author":"Val-Blasco","year":"2017","journal-title":"Biochem J."},{"key":"10.1016\/j.addr.2021.01.004_bb0255","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/08977194.2013.852189","article-title":"Protective effect of statin therapy on connective tissue growth factor induction by diabetes in vivo and high glucose in vitro","volume":"31","author":"Yang","year":"2013","journal-title":"Growth Factors."},{"key":"10.1016\/j.addr.2021.01.004_bb0260","doi-asserted-by":"crossref","first-page":"539787","DOI":"10.1155\/2015\/539787","article-title":"Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction","volume":"2015","author":"Gerritsen","year":"2015","journal-title":"J Diabetes Res."},{"key":"10.1016\/j.addr.2021.01.004_bb0265","doi-asserted-by":"crossref","first-page":"44187","DOI":"10.1074\/jbc.M203715200","article-title":"The role of p42\/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells","volume":"277","author":"Crean","year":"2002","journal-title":"J Biol Chem."},{"key":"10.1016\/j.addr.2021.01.004_bb0270","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1096\/fj.05-5010fje","article-title":"Connective tissue growth factor\/CCN2 stimulates actin disassembly through Akt\/protein kinase B-mediated phosphorylation and cytoplasmic translocation of p27(Kip-1)","volume":"20","author":"Crean","year":"2006","journal-title":"Faseb J."},{"key":"10.1016\/j.addr.2021.01.004_bb0275","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1042\/BJ20061817","article-title":"Connective tissue growth factor (CTGF) promotes activated mesangial cell survival via up-regulation of mitogen-activated protein kinase phosphatase-1 (MKP-1)","volume":"406","author":"Wahab","year":"2007","journal-title":"Biochem J."},{"key":"10.1016\/j.addr.2021.01.004_bb0280","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrneph.2014.14","article-title":"Potential approaches to reverse or repair renal fibrosis","volume":"10","author":"Tampe","year":"2014","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.addr.2021.01.004_bb0285","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1681\/ASN.2013070723","article-title":"Tet3-mediated hydroxymethylation of epigenetically silenced genes contributes to bone morphogenic protein 7-induced reversal of kidney fibrosis","volume":"25","author":"Tampe","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.addr.2021.01.004_bb0290","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCRESAHA.119.314794","article-title":"Yin Yang 1 Suppresses Dilated Cardiomyopathy and Cardiac Fibrosis Through Regulation of Bmp7 and Ctgf","volume":"125","author":"Tan","year":"2019","journal-title":"Circ Res."},{"key":"10.1016\/j.addr.2021.01.004_bb0295","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.2016.9400","article-title":"Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis","volume":"316","author":"Palmer","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.addr.2021.01.004_bb0300","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","author":"Newsome","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.004_bb0305","article-title":"Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus","volume":"10","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.addr.2021.01.004_bb0310","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.carrev.2017.11.003","article-title":"Robotically-assisted percutaneous coronary intervention: Reasons for partial manual assistance or manual conversion","volume":"19","author":"Harrison","year":"2018","journal-title":"Cardiovasc Revasc Med."},{"key":"10.1016\/j.addr.2021.01.004_bb0315","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA."},{"key":"10.1016\/j.addr.2021.01.004_bb0320","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/HYPERTENSIONAHA.120.14791","article-title":"Opportunities of Antidiabetic Drugs in Cardiovascular Medicine: A Meta-Analysis and Perspectives for Trial Design","volume":"76","author":"Yan","year":"2020","journal-title":"Hypertension."},{"key":"10.1016\/j.addr.2021.01.004_bb0325","doi-asserted-by":"crossref","first-page":"F596","DOI":"10.1152\/ajprenal.00365.2015","article-title":"TGF-beta signaling in the kidney: profibrotic and protective effects","volume":"310","author":"Sureshbabu","year":"2016","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.addr.2021.01.004_bb0330","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ki.2015.51","article-title":"Renal fibrosis is not reduced by blocking transforming growth factor-beta signaling in matrix-producing interstitial cells","volume":"88","author":"Neelisetty","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.01.004_bb0335","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1681\/ASN.2009121244","article-title":"Smad2 protects against TGF-beta\/Smad3-mediated renal fibrosis","volume":"21","author":"Meng","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.addr.2021.01.004_bb0340","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.addr.2010.02.002","article-title":"Nanomaterials for in situ cell delivery and tissue regeneration","volume":"62","author":"Wan","year":"2010","journal-title":"Adv Drug Deliv Rev."},{"key":"10.1016\/j.addr.2021.01.004_bb0345","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ejmech.2019.01.007","article-title":"Composition design and medical application of liposomes","volume":"164","author":"Li","year":"2019","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.addr.2021.01.004_bb0350","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3109\/1061186X.2014.934688","article-title":"Polymeric micelles as drug carriers: their lights and shadows","volume":"22","author":"Yokoyama","year":"2014","journal-title":"J Drug Target."},{"key":"10.1016\/j.addr.2021.01.004_bb0355","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/molecules23040938","article-title":"Dendrimers for Drug Delivery","volume":"23","author":"Chauhan","year":"2018","journal-title":"Molecules."},{"key":"10.1016\/j.addr.2021.01.004_bb0360","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijpharm.2018.07.030","article-title":"Dendrimers: A versatile nanocarrier for drug delivery and targeting","volume":"548","author":"Sherje","year":"2018","journal-title":"Int J Pharm."},{"key":"10.1016\/j.addr.2021.01.004_bb0365","doi-asserted-by":"crossref","first-page":"178","DOI":"10.31768\/2312-8852.2018.40(3):178-183","article-title":"Role of dendrimers in advanced drug delivery and biomedical applications: a review","volume":"40","author":"Akbarzadeh","year":"2018","journal-title":"Exp Oncol."},{"key":"10.1016\/j.addr.2021.01.004_bb0370","first-page":"639","article-title":"Medicinal applications of fullerenes","volume":"2","author":"Bakry","year":"2007","journal-title":"Int J Nanomedicine."},{"key":"10.1016\/j.addr.2021.01.004_bb0375","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/187220811796365707","article-title":"Recent progresses in application of fullerenes in cosmetics","volume":"5","author":"Lens","year":"2011","journal-title":"Recent Pat Biotechnol."},{"key":"10.1016\/j.addr.2021.01.004_bb0380","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1166\/jbn.2014.1963","article-title":"Functionalized fullerenes in photodynamic therapy","volume":"10","author":"Huang","year":"2014","journal-title":"J Biomed Nanotechnol."},{"key":"10.1016\/j.addr.2021.01.004_bb0385","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.21037\/jtd.2017.01.29","article-title":"Single-port video-assisted thoracoscopic surgery for a huge epiphrenic esophageal diverticulum","volume":"9","author":"Kang","year":"2017","journal-title":"J Thorac Dis."},{"key":"10.1016\/j.addr.2021.01.004_bb0390","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/bi020496s","article-title":"Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease","volume":"42","author":"Zhu","year":"2003","journal-title":"Biochemistry."},{"key":"10.1016\/j.addr.2021.01.004_bb0395","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.biotechadv.2018.10.010","article-title":"The Yin and Yang of carbon nanomaterials in atherosclerosis","volume":"36","author":"Rezaee","year":"2018","journal-title":"Biotechnol Adv."},{"key":"10.1016\/j.addr.2021.01.004_bb0400","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omtn.2017.06.004","article-title":"Reducible PEG-POD\/DNA Nanoparticles for Gene Transfer In Vitro and In Vivo: Application in a Mouse Model of Age-Related Macular Degeneration","volume":"8","author":"Dasari","year":"2017","journal-title":"Mol Ther Nucleic Acids."},{"key":"10.1016\/j.addr.2021.01.004_bb0405","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jconrel.2010.04.031","article-title":"Reducible DNA nanoparticles enhance in vitro gene transfer via an extracellular mechanism","volume":"146","author":"Sun","year":"2010","journal-title":"J Control Release."},{"key":"10.1016\/j.addr.2021.01.004_bb0410","first-page":"e301","article-title":"A review on protein functionalized carbon nanotubes","volume":"13","author":"Nagaraju","year":"2015","journal-title":"J Appl Biomater Funct Mater."},{"key":"10.1016\/j.addr.2021.01.004_bb0415","first-page":"5464","article-title":"Pachymic acid modified carbon nanoparticles reduced angiogenesis via inhibition of MMP-3","volume":"8","author":"Ma","year":"2015","journal-title":"Int J Clin Exp Pathol."},{"key":"10.1016\/j.addr.2021.01.004_bb0420","doi-asserted-by":"crossref","first-page":"23353","DOI":"10.1021\/acsami.7b04971","article-title":"Synergistic Suppression of Tumor Angiogenesis by the Co-delivering of Vascular Endothelial Growth Factor Targeted siRNA and Candesartan Mediated by Functionalized Carbon Nanovectors","volume":"9","author":"Ding","year":"2017","journal-title":"ACS Appl Mater Interfaces."},{"key":"10.1016\/j.addr.2021.01.004_bb0425","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/jon.12318","article-title":"USPIO-Enhanced MRI Neuroimaging: A Review","volume":"26","author":"Gkagkanasiou","year":"2016","journal-title":"J Neuroimaging."},{"key":"10.1016\/j.addr.2021.01.004_bb0430","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1007\/s00330-019-06277-7","article-title":"USPIO-enhanced MRI of pelvic lymph nodes at 7-T: preliminary experience","volume":"29","author":"Philips","year":"2019","journal-title":"Eur Radiol."},{"key":"10.1016\/j.addr.2021.01.004_bb0435","article-title":"Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One."},{"key":"10.1016\/j.addr.2021.01.004_bb0440","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1477-3155-8-33","article-title":"Size-dependent endocytosis of gold nanoparticles studied by three-dimensional mapping of plasmonic scattering images","volume":"8","author":"Wang","year":"2010","journal-title":"J Nanobiotechnology."},{"key":"10.1016\/j.addr.2021.01.004_bb0445","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1166\/jnn.2015.10321","article-title":"Integration of Peptides for Enhanced Uptake of PEGylayed Gold Nanoparticles","volume":"15","author":"Cruje","year":"2015","journal-title":"J Nanosci Nanotechnol."},{"key":"10.1016\/j.addr.2021.01.004_bb0450","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/nnm.16.5","article-title":"The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction","volume":"11","author":"Hoshyar","year":"2016","journal-title":"Nanomedicine (Lond)."},{"key":"10.1016\/j.addr.2021.01.004_bb0455","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/IJN.S198353","article-title":"Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives","volume":"14","author":"Mukherjee","year":"2019","journal-title":"Int J Nanomedicine."},{"key":"10.1016\/j.addr.2021.01.004_bb0460","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s10439-016-1583-9","article-title":"Nanoparticle-Hydrogel: A Hybrid Biomaterial System for Localized Drug Delivery","volume":"44","author":"Gao","year":"2016","journal-title":"Ann Biomed Eng."},{"key":"10.1016\/j.addr.2021.01.004_bb0465","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1021\/acsnano.6b08551","article-title":"Inhaled Nanoparticles Accumulate at Sites of Vascular Disease","volume":"11","author":"Miller","year":"2017","journal-title":"ACS Nano."},{"key":"10.1016\/j.addr.2021.01.004_bb0470","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.addr.2019.07.006","article-title":"Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications","volume":"144","author":"Mohammadpour","year":"2019","journal-title":"Adv Drug Deliv Rev."},{"key":"10.1016\/j.addr.2021.01.004_bb0475","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1039\/B715310D","article-title":"Autonomous propulsion of carbon nanotubes powered by a multienzyme ensemble","author":"Pantarotto","year":"2008","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.addr.2021.01.004_bb0480","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0748233717747472","article-title":"Toxicity of carbon nanotubes: A review","volume":"34","author":"Francis","year":"2018","journal-title":"Toxicol Ind Health."},{"key":"10.1016\/j.addr.2021.01.004_bb0485","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.immuni.2016.02.024","article-title":"Tissue-Resident Macrophage Ontogeny and Homeostasis","volume":"44","author":"Ginhoux","year":"2016","journal-title":"Immunity."},{"key":"10.1016\/j.addr.2021.01.004_bb0490","doi-asserted-by":"crossref","first-page":"16632","DOI":"10.1038\/srep16632","article-title":"Modulation of Macrophage Functional Polarity towards Anti-Inflammatory Phenotype with Plasmid DNA Delivery in CD44 Targeting Hyaluronic Acid Nanoparticles","volume":"5","author":"Tran","year":"2015","journal-title":"Sci Rep."},{"key":"10.1016\/j.addr.2021.01.004_bb0495","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.addr.2011.06.002","article-title":"Material properties in complement activation","volume":"63","author":"Moghimi","year":"2011","journal-title":"Adv Drug Deliv Rev."},{"key":"10.1016\/j.addr.2021.01.004_bb0500","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.smim.2017.08.013","article-title":"Nanoparticles and innate immunity: new perspectives on host defence","volume":"34","author":"Boraschi","year":"2017","journal-title":"Semin Immunol."},{"key":"10.1016\/j.addr.2021.01.004_bb0505","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/anie.201004655","article-title":"Uniform lipopolysaccharide (LPS)-loaded magnetic nanoparticles for the investigation of LPS-TLR4 signaling","volume":"50","author":"Piazza","year":"2011","journal-title":"Angew Chem Int Ed Engl."},{"key":"10.1016\/j.addr.2021.01.004_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096584","article-title":"Size-dependent effects of gold nanoparticles uptake on maturation and antitumor functions of human dendritic cells in vitro","volume":"9","author":"Tomic","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.addr.2021.01.004_bb0515","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cbi.2015.04.011","article-title":"The impact of cationic solid lipid nanoparticles on human neutrophil activation and formation of neutrophil extracellular traps (NETs)","volume":"235","author":"Hwang","year":"2015","journal-title":"Chem Biol Interact."},{"key":"10.1016\/j.addr.2021.01.004_bb0520","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.intimp.2015.06.030","article-title":"Silver nanoparticles rapidly induce atypical human neutrophil cell death by a process involving inflammatory caspases and reactive oxygen species and induce neutrophil extracellular traps release upon cell adhesion","volume":"28","author":"Liz","year":"2015","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.addr.2021.01.004_bb0525","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Investigators","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.addr.2021.01.004_bb0530","first-page":"966","article-title":"Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice","volume":"25","author":"Wu","year":"2004","journal-title":"Acta Pharmacol Sin."},{"key":"10.1016\/j.addr.2021.01.004_bb0535","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.biomaterials.2011.10.075","article-title":"Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport","volume":"33","author":"Jin","year":"2012","journal-title":"Biomaterials."},{"key":"10.1016\/j.addr.2021.01.004_bb0540","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2016.1176822","article-title":"Safety concerns over the use of intestinal permeation enhancers: A mini-review","volume":"4","author":"McCartney","year":"2016","journal-title":"Tissue Barriers."},{"key":"10.1016\/j.addr.2021.01.004_bb0545","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpharm.2014.11.047","article-title":"Improved insulin loading in poly(lactic-co-glycolic) acid (PLGA) nanoparticles upon self-assembly with lipids","volume":"482","author":"Garcia-Diaz","year":"2015","journal-title":"Int J Pharm."},{"key":"10.1016\/j.addr.2021.01.004_bb0550","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/1556-276X-9-185","article-title":"Enhanced hypoglycemic effect of biotin-modified liposomes loading insulin: effect of formulation variables, intracellular trafficking, and cytotoxicity","volume":"9","author":"Zhang","year":"2014","journal-title":"Nanoscale Res Lett."},{"key":"10.1016\/j.addr.2021.01.004_bb0555","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/jbm.a.36777","article-title":"Three-dimensional cryogels for biomedical applications","volume":"107","author":"Razavi","year":"2019","journal-title":"J Biomed Mater Res A."},{"key":"10.1016\/j.addr.2021.01.004_bb0560","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1039\/c3tb20487a","article-title":"Electrospun composite nanofiber-based transmucosal patch for anti-diabetic drug delivery","volume":"1","author":"Sharma","year":"2013","journal-title":"J Mater Chem B."},{"key":"10.1016\/j.addr.2021.01.004_bb0565","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1021\/bm401580k","article-title":"Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration","volume":"15","author":"Agrawal","year":"2014","journal-title":"Biomacromolecules."},{"key":"10.1016\/j.addr.2021.01.004_bb0570","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2021.01.004_bb0575","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/10717544.2013.779332","article-title":"Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system","volume":"20","author":"Hasan","year":"2013","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2021.01.004_bb0580","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejpb.2019.08.015","article-title":"Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications","volume":"144","author":"Chen","year":"2019","journal-title":"Eur J Pharm Biopharm."},{"key":"10.1016\/j.addr.2021.01.004_bb0585","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.addr.2021.01.004_bb0590","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.2147\/IJN.S132064","article-title":"Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction","volume":"12","author":"Qi","year":"2017","journal-title":"Int J Nanomedicine."},{"issue":"Pt 3","key":"10.1016\/j.addr.2021.01.004_bb0595","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/hdy.1988.58","article-title":"The alcohol dehydrogenase polymorphism of Drosophila melanogaster in relation to environmental ethanol, ethanol tolerance and alcohol dehydrogenase activity","volume":"60","author":"Gibson","year":"1988","journal-title":"Heredity (Edinb)."},{"key":"10.1016\/j.addr.2021.01.004_bb0600","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2019.12.014","article-title":"A polyphenol-metal nanoparticle platform for tunable release of liraglutide to improve blood glycemic control and reduce cardiovascular complications in a mouse model of type II diabetes","volume":"318","author":"He","year":"2020","journal-title":"J Control Release."},{"key":"10.1016\/j.addr.2021.01.004_bb0605","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/ard.47.9.725","article-title":"Lymphocytotoxic antibodies in systemic lupus erythematosus: studies of their temperature dependence, binding characteristics, and specificity in vitro","volume":"47","author":"Peake","year":"1988","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.addr.2021.01.004_bb0610","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/aos.12803","article-title":"Topical dexamethasone gamma-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema","volume":"93","author":"Ohira","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.addr.2021.01.004_bb0615","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ctim.2019.02.014","article-title":"Nano curcumin supplementation reduced the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes mellitus: A randomized double-blind placebo- controlled clinical trial","volume":"43","author":"Asadi","year":"2019","journal-title":"Complement Ther Med."},{"key":"10.1016\/j.addr.2021.01.004_bb0620","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ptr.6571","article-title":"Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial","volume":"34","author":"Asadi","year":"2020","journal-title":"Phytother Res."},{"key":"10.1016\/j.addr.2021.01.004_bb0625","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00784-019-03005-9","article-title":"Novel 20% doxycycline-loaded PLGA nanospheres as adjunctive therapy in chronic periodontitis in type-2 diabetics: randomized clinical, immune and microbiological trial","volume":"24","author":"Lecio","year":"2020","journal-title":"Clin Oral Investig."},{"key":"10.1016\/j.addr.2021.01.004_bb0630","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1932296814524871","article-title":"A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus","volume":"8","author":"Geho","year":"2014","journal-title":"J Diabetes Sci Technol."},{"key":"10.1016\/j.addr.2021.01.004_bb0635","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/clc.20066","article-title":"Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-in-human safety and dose-finding study","volume":"30","author":"Margolis","year":"2007","journal-title":"Clin Cardiol."},{"key":"10.1016\/j.addr.2021.01.004_bb0640","doi-asserted-by":"crossref","first-page":"6878","DOI":"10.1021\/acsnano.0c01007","article-title":"Targeted Delivery of Notch Inhibitor Attenuates Obesity-Induced Glucose Intolerance and Liver Fibrosis","volume":"14","author":"Richter","year":"2020","journal-title":"ACS Nano."},{"key":"10.1016\/j.addr.2021.01.004_bb0645","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3389\/fphar.2018.01341","article-title":"In vivo and in vitro Approach to Anti-arthritic and Anti-inflammatory Effect of Crocetin by Alteration of Nuclear Factor-E2-Related Factor 2\/hem Oxygenase (HO)-1 and NF-kappaB Expression","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.addr.2021.01.004_bb0650","doi-asserted-by":"crossref","DOI":"10.1088\/2050-6120\/aaf0ca","article-title":"A fluorescent aptamer\/carbon dots based assay for Cytochrome c protein detection as a biomarker of cell apoptosis","volume":"7","author":"Ghayyem","year":"2018","journal-title":"Methods Appl Fluoresc."},{"key":"10.1016\/j.addr.2021.01.004_bb0655","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/IJN.S176013","article-title":"Amelioration of diabetic nephropathy using pomegranate peel extract-stabilized gold nanoparticles: assessment of NF-kappaB and Nrf2 signaling system","volume":"14","author":"Manna","year":"2019","journal-title":"Int J Nanomedicine."},{"key":"10.1016\/j.addr.2021.01.004_bb0660","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1076029614551822","article-title":"Efficacy of Heparinoid PSS in Treating Cardiovascular Diseases and Beyond-A Review of 27 Years Clinical Experiences in China","volume":"22","author":"Zeng","year":"2016","journal-title":"Clin Appl Thromb Hemost."},{"key":"10.1016\/j.addr.2021.01.004_bb0665","doi-asserted-by":"crossref","first-page":"109280","DOI":"10.1016\/j.biopha.2019.109280","article-title":"Effects and mechanisms of PSS-loaded nanoparticles on coronary microcirculation dysfunction in streptozotocin-induced diabetic cardiomyopathy rats","volume":"121","author":"Mao","year":"2020","journal-title":"Biomed Pharmacother."},{"key":"10.1016\/j.addr.2021.01.004_bb0670","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2147\/IJN.S153763","article-title":"In vitro\/vivo drug release and anti-diabetic cardiomyopathy properties of curcumin\/PBLG-PEG-PBLG nanoparticles","volume":"13","author":"Tong","year":"2018","journal-title":"Int J Nanomedicine."},{"key":"10.1016\/j.addr.2021.01.004_bb0675","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1080\/03639045.2019.1672717","article-title":"Curcumin loaded mesoporous silica nanoparticles: assessment of bioavailability and cardioprotective effect","volume":"45","author":"Yadav","year":"2019","journal-title":"Drug Dev Ind Pharm."},{"key":"10.1016\/j.addr.2021.01.004_bb0680","doi-asserted-by":"crossref","unstructured":"M. Miragoli, P. Ceriotti, M. Iafisco, M. Vacchiano, N. Salvarani, A. Alogna, P. Carullo, G.B. Ramirez-Rodriguez, T. Patricio, L.D. Esposti, F. Rossi, F. Ravanetti, S. Pinelli, R. Alinovi, M. Erreni, S. Rossi, G. Condorelli, H. Post, A. Tampieri, D. Catalucci, Inhalation of peptide-loaded nanoparticles improves heart failure, Sci Transl Med. 10 (2018) eaan6205.","DOI":"10.1126\/scitranslmed.aan6205"},{"key":"10.1016\/j.addr.2021.01.004_bb0685","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jtemb.2017.04.013","article-title":"Comparative study of cardio-protective effects of zinc oxide nanoparticles and zinc sulfate in streptozotocin-induced diabetic rats","volume":"42","author":"Asri-Rezaei","year":"2017","journal-title":"J Trace Elem Med Biol."},{"key":"10.1016\/j.addr.2021.01.004_bb0690","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/j.1742-4658.2010.07632.x","article-title":"MicroRNAs and the regulation of fibrosis","volume":"277","author":"Jiang","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.addr.2021.01.004_bb0695","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1101\/gad.1738708","article-title":"microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart","volume":"22","author":"Liu","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.addr.2021.01.004_bb0700","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/CIRCRESAHA.108.182535","article-title":"miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling","volume":"104","author":"Duisters","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.addr.2021.01.004_bb0705","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/cvr\/cvp130","article-title":"Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines","volume":"83","author":"Shan","year":"2009","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.addr.2021.01.004_bb0710","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cancergencyto.2008.10.013","article-title":"Selection of optimal sites for TGFB1 gene silencing by chitosan-TPP nanoparticle-mediated delivery of shRNA","volume":"190","author":"Wang","year":"2009","journal-title":"Cancer Genet Cytogenet."},{"key":"10.1016\/j.addr.2021.01.004_bb0715","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/gt.2014.116","article-title":"TGF-beta(1)-siRNA delivery with nanoparticles inhibits peritoneal fibrosis","volume":"22","author":"Yoshizawa","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2021.01.004_bb0720","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/CIRCULATIONAHA.119.039767","article-title":"Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-beta1-Endothelin-1 Signal Pathway","volume":"140","author":"Liu","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.addr.2021.01.004_bb0725","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.biomaterials.2012.09.067","article-title":"Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis","volume":"34","author":"Kong","year":"2013","journal-title":"Biomaterials."},{"key":"10.1016\/j.addr.2021.01.004_bb0730","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/nano6010008","article-title":"Targeted Sterically Stabilized Phospholipid siRNA Nanomedicine for Hepatic and Renal Fibrosis","volume":"6","author":"Khaja","year":"2016","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.addr.2021.01.004_bb0735","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.1074\/jbc.M115.693671","article-title":"Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis","volume":"291","author":"Yoon","year":"2016","journal-title":"J Biol Chem."},{"key":"10.1016\/j.addr.2021.01.004_bb0740","doi-asserted-by":"crossref","first-page":"F777","DOI":"10.1152\/ajprenal.00653.2013","article-title":"Nanotechnology and adeno-associated virus-based decorin gene therapy ameliorates peritoneal fibrosis","volume":"307","author":"Chaudhary","year":"2014","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.addr.2021.01.004_bb0745","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.2147\/IJN.S82587","article-title":"Delivery of microRNA-146a with polyethylenimine nanoparticles inhibits renal fibrosis in vivo","volume":"10","author":"Morishita","year":"2015","journal-title":"Int J Nanomedicine."},{"key":"10.1016\/j.addr.2021.01.004_bb0750","doi-asserted-by":"crossref","first-page":"31938","DOI":"10.1021\/acsami.8b10527","article-title":"Inorganic Nanomaterials as Highly Efficient Inhibitors of Cellular Hepatic Fibrosis","volume":"10","author":"Peng","year":"2018","journal-title":"ACS Appl Mater Interfaces."},{"key":"10.1016\/j.addr.2021.01.004_bb0755","doi-asserted-by":"crossref","first-page":"eaaw4949","DOI":"10.1126\/scitranslmed.aaw4949","article-title":"Advances in artificial pancreas systems","volume":"11","author":"Boughton","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.addr.2021.01.004_bb0760","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S2213-8587(17)30167-5","article-title":"Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials","volume":"5","author":"Weisman","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.addr.2021.01.004_bb0765","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","article-title":"Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways","volume":"142","author":"Huynh","year":"2014","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.addr.2021.01.004_bb0770","doi-asserted-by":"crossref","first-page":"118720","DOI":"10.1016\/j.ijpharm.2019.118720","article-title":"Bio-nanotechnological advancement of orally administered insulin nanoparticles: Comprehensive review of experimental design for physicochemical characterization","volume":"572","author":"Wong","year":"2019","journal-title":"Int J Pharm."},{"key":"10.1016\/j.addr.2021.01.004_bb0775","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2213-8587(18)30372-3","article-title":"Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial","volume":"7","author":"Halberg","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.addr.2021.01.004_bb0780","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/dom.13907","article-title":"Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes","volume":"22","author":"Gastaldelli","year":"2020","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.addr.2021.01.004_bb0785","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1007\/s00125-016-4100-7","article-title":"Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial","volume":"59","author":"Smits","year":"2016","journal-title":"Diabetologia."},{"key":"10.1016\/j.addr.2021.01.004_bb0790","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.addr.2021.01.004_bb0795","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1053\/j.ajkd.2012.06.005","article-title":"Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial","volume":"60","author":"Fallahzadeh","year":"2012","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.addr.2021.01.004_bb0800","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MEG.0b013e32832e2baf","article-title":"Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease","volume":"22","author":"Omer","year":"2010","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.addr.2021.01.004_bb0805","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jjcc.2009.03.004","article-title":"Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients","volume":"54","author":"Terui","year":"2009","journal-title":"J Cardiol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:02:12Z","timestamp":1759208532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":161,"alternative-id":["S0169409X21000041"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2021.01.004","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanomedicine for the treatment of diabetes-associated cardiovascular diseases and fibrosis","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}